Skip to main content
Premium Trial:

Request an Annual Quote

Celera Bolsters CDS Content with Full-Length Clones in AlphaGene Distribution Agreement


In the latest of a series of partnerships to expand the capabilities of its subscription database, Celera Genomics is teaming with AlphaGene of Woburn, Mass., to distribute AlphaGene’s collection of human full-length gene clones through the Celera Discovery System.

Under the terms of the agreement, AlphaGene will isolate known clones in the public domain and Celera will map the clone sequences to its assembled human genome database. CDS subscribers will be able to order specific clones through the Celera website, and AlphaGene will fully sequence and manufacture them.

The clones are expected to be available through CDS in the first quarter of 2002.

Celera and AlphaGene will share revenue in the marketing effort. Further financial details of the agreement were not disclosed.

The move is in line with a number of deals Celera has entered in the last two months to beef up the CDS service. The company most recently partnered with Inpharmatica to add structural and functional data to its genomic content. In October Celera entered a marketing and distribution agreement for the ModBase protein structure database from Structural GenomiX, and signed a non-exclusive license for Virtual Genetics’ Virtual Adapt bioinformatics text mining technology for use in CDS.

The AlphaGene deal, however, is the first to provide CDS subscribers with anything but data through the website. The clones are in the public domain, so neither Celera nor AlphaGene stands to benefit from IP-based revenues. However, the new capability does bring Celera’s offering one step closer to that of its primary rival in the genomic data market, Incyte, whose LifeSeq database offers proprietary clones as well as genomic data.

Peter Schad, CSO of AlphaGene, said that his company’s clones differ from Incyte’s because “we’re providing full-length clones.” AlphaGene uses its proprietary Flex technology to produce full-length gene libraries of known and novel clones, he said.

While only publicly available clones are covered under the current distribution agreement, Schad said that future plans might involve making AlphaGene’s proprietary clones available through the CDS as well.

“Over time I hope to broaden the deal to include many of the unknown and novel genes that we have with the Celera project,” Schad said, noting that the companies chose to keep the deal “simple” for now to avoid complicated IP issues that would arise over proprietary genes.

Schad described the current deal as “an experiment” to determine the market demand for clones.

— BT

Filed under

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.